Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
CAMBRIDGE, Mass., April 05, 2018 -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will be participating at the following conferences:
| H.C. Wainwright & Co. Global Life Sciences Conference April 9th at 9:00 a.m. CEST – Monte Carlo, Monaco Leerink Partners’ CNS Day April 18th at 10:00 a.m. EST – New York, NY |
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.
Investor Contact:
Jillian Connell
617-949-2981
[email protected]
Media Contact:
Jose Juves
617-949-4708
[email protected]
